The goal of this observational survey study is to investigate factors that may affect the health-related quality of life (HRQoL) in adults with Chiari malformation type 1 (CM1). The main questions it aims to answer are:
How do CM1 patients rate their HRQoL compared to the general population? Are there any factors that lead to better or worse HRQoL in CM1 patients? Is there a difference in HRQoL in operated versus non-operated CM1 patients?
Participants will be identified via the Swedish National Board of Health and Welfare's Patient register. They will be asked to participate in a survey of HRQoL containing standardized questionnaires, and their answers will be analyzed together with data from the Patient register. Their questionnaire answers will also be compared to normative Swedish data.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* diagnosis of Arnold Chiari Malformation (ICD-code Q07.0)
* for operated patients: record of posterior fossa decompression (procedure code ABE50)
* for non-operated patients: the diagnosis Q07.0 recorded during an outpatient visit to a neurosurgical unit
Exclusion Criteria:
* record of spina bifida diagnosis (Q05.X)
* for non-operated patients: record of the procedures duraplasty (procedure code AAK10) or another operation on the cranium or dura (procedure code AAK99)
Primary outcome measure(s)
EQ-5D index score — Baseline Combined value of the five dimensions of the Euroqol five-dimensional three level (EQ-5D-3L) questionnaire, based on the United Kingdom value set. The index score has a value between 0 and 1, where 1 represents full health.
EQ-5D VAS score — Baseline The Euroqol five-dimensonial (EQ-5D) visual analog scale (VAS). The respondents rate their current health between 0 (worst imaginable health) and 100 (best imaginable health).
Trial sites (1)
Facility
City
Region
Status
Department of Clinical Neuroscience, Karolinska Institutet
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.